Egen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.egeninc.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01300858
- Locations
- 🇺🇸
Midwestern Regional Medical Center, Zion, Illinois, United States
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
Phase 1
Completed
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00473954
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Oncology Specialties, PC, Huntsville, Alabama, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
Phase 1
Terminated
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00137865
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
News
No news found